Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction

Introduction

Childhood asthma is a global problem with substantial variation in asthma prevalence worldwide.¹ In the USA, it is estimated that 6.2 million children <18 years have asthma,² the equivalent of 8.4% or 1 in 12 children. The prevalence of childhood asthma in the European Union is very similar with an estimated 9.4% of children diagnosed and treated for the condition.³

Childhood asthma frequently starts in the early years as preschool wheeze. Several epidemiological phenotypes have been described in North America⁴ and Europe.^5–7 Three epidemiological phenotypes are recognised in both continents:⁸ (a) transient early wheeze which starts before the age of 3 years and resolves by age 6, (b) late-onset wheeze which starts 3 years of age and persists in childhood, and (c) persistent wheeze which starts before 3 years of age and persists into school age. The clinical phenotypes are described as episodic viral wheeze and multiple trigger wheeze,^9,10 but there is considerable overlap and movement between the clinical phenotypes over time.¹¹ Children with preschool episodic viral wheeze often become asymptomatic when reaching school age.⁵ However, these children still show lung function deficits as young adults and low level eosinophilic airway inflammation.¹² Preschool disease markers predicting the development of severe asthma in older children are lacking; however, a recent study suggests that early sensitisation to thermotolerant fungi is associated with worse lung function in children with asthma.¹³

Asthma severity is a spectrum but most children with asthma are controlled with regular use of low-to-medium doses of inhaled corticosteroids (ICS) with or without additional controller drugs. Severe asthma constitutes the extreme end of the asthma spectrum. The European Respiratory Society (ERS)/American Thoracic Society (ATS) Task Force defines severe asthma in people ≥6 years in the following way; asthma that requires treatment with high dose ICS and long-acting beta-2 agonist (LABA) or leukotriene receptor antagonists (LTRA) or theophylline at GINA steps 4–5¹⁴ for the previous year or the need for systemic corticosteroids (CS) for ≥50% of the previous year to prevent the asthma from becoming “uncontrolled” or which remains “uncontrolled” despite this therapy.¹⁵ Uncontrolled asthma is defined by the presence of one of: a) poor symptom control score, b) ≥3 bursts of systemic corticosteroids, c) one or more hospitalisations in the previous 12 months, or d) airflow limitation (forced expiratory volume in 1st second (FEV₁) <80% predicted and the Tiffeneau-Pinelli index (FEV₁/forced vital capacity (FVC)) < lower limit of normal).

These diagnostic criteria for severe asthma are fairly rigid and do not take into account that only a small proportion of children with asthma is followed in specialist care settings. Asthma severity in non-specialist settings is probably underestimated in a significant number of children.¹⁶ Estimating the number of children with severe asthma therefore is difficult and it is not surprising that the data varies from country to country and in different healthcare settings.¹ Recent reports from Europe¹⁷ and North America¹⁸ suggest that the prevalence of severe asthma is approximately 1% to 5% of the child asthma population.¹

Children with severe asthma have a disproportionately high healthcare burden due to the frequency of asthma attacks experienced by this group of children in combination with the cost of high-dose ICS and other preventer and rescue medication.¹⁹ High-cost therapies such as the newly available monoclonal antibodies are playing their part in the escalating cost of severe childhood asthma.

Classification of Severe Childhood Asthma

Problematic Severe Asthma

The term problematic severe asthma has been used to describe children with a poor clinical response despite prescription of high dose preventer medication.^20,21 After careful clinical evaluation, which includes confirmation that asthma is the correct diagnosis, these children fall broadly into two categories although there can be considerable overlap; children with difficult-to-treat asthma with or without comorbidities and children with severe therapy resistant asthma.

Difficult-to-Treat Asthma

This group includes children where modifiable factors including comorbidities contribute to asthma severity. These children often become controlled when these factors are addressed. Modifiable factors include poor medication adherence,²² exposure to environmental factors such as pet allergens²³ and other indoor allergens such as fungi,¹³ exposure to tobacco smoke,²⁴ air pollution,²⁵ and psychosocial factors.²⁶

Comorbidities

Important comorbidities include dysfunctional breathing,²⁷ allergic rhinitis,²⁸ sinusitis,²⁹ anxiety and depression,³⁰ and obesity.³¹ The evidence however suggests that treatment of allergic rhinitis does not improve asthma symptoms in either children or adults where both conditions co-exist.³²

Home visits are important because they allow the asthma team to get an impression of the home environment. The visit can identify ongoing allergen exposure to dust, moulds, pets, exposure to second hand tobacco smoke or vaping and other pollutants.³³ The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) is a European project involving 16 centres in 11 countries in Europe³⁴ conducted over five years between 2010 and 2014³⁵ found that 23% of children with severe asthma had evidence of exposure to environmental tobacco smoke.¹⁹ Identification of this trigger is important and a change in parent or young person behavior should be encouraged.³⁶ Recent data from Scotland highlight the benefits of a smoke-free home intervention to decreases asthma attacks in children.³⁷

Severe Therapy-Resistant Asthma (STRA)

This term describes children who remain uncontrolled on high dose preventer medication after modifiable factors including comorbidities have been addressed.³⁸ Importantly, good adherence to preventer medication using technology is required to confirm the presence of STRA.³⁹ These children may be considered for biologics as an add-on therapy.

Adherence

Poor adherence to asthma preventer medication is common and contributes substantially to the number of children labelled as severe asthma that have in fact mild-moderate asthma. A recent study of 93 children³⁹ attending a specialist severe asthma clinic found that 58% of children showed poor adherence (<80%) despite the fact that the children and families knew that they were monitored, which by itself may have boosted adherence. In addition, 14% dropped out from the original cohort of 108 children.

There is poor correlation between reported and actual adherence and therefore some form of electronic monitoring is essential in the assessment of children with problematic severe asthma. The World Health Organisation⁴⁰ defines poor adherence as erratic nonadherence, unwitting nonadherence and intelligent nonadherence. Interventions to improve adherence need to be tailored to the pattern of non-adherence⁴¹ and to the needs of families and children in order to be effective.

Inhaler Technique

Children and young people should be prescribed pressurized metered dose inhalers (pMDI) with spacers or dry powder inhalers. Inhaler technique must be demonstrated and practiced with the child each time a new device is prescribed³⁹ and yearly thereafter.⁴² Poor inhaler technique is common in patients with asthma including children^43,44 and can be the reason for poor control despite high doses of prescribed ICS.⁴⁵ A recent study found inhaler technique found mistakes in the majority of children attending a severe asthma clinic and it took on average three weeks of daily observedMobile Remote Video Directly Observed Therapy (MDOT) with coaching before good inhaler technique was established.⁴⁶ The asthma symptoms improved in all children but the effect of adherence monitoring and improved inhaler technique is difficult to disentangle. In children, directly observed administration of morning dose ICS in school settings is also linked with better asthma control.⁴⁷

Phenotyping of Severe Pediatric Asthma Patients to Identify Treatable Traits

Precision Medicine

This refers to a personalised approach to patient care by choosing a treatment for the individual patient based on his/her specific characteristics or treatable traits, rather than adopting a “one size fits all” attitude. It requires the identification of treatable traits using deep phenotyping, including genetic, immunological, environmental, and lifestyle factors to identify relevant targeted treatments.^48,49

Asthma Phenotypes

Five biologic therapies are now available to treat adults with asthma⁵⁰ and two for children. This number is likely to increase and accurate phenotyping to identify responder profiles to these biologics is essential for precision medicine. Type 2 (T2) inflammation characterised by the mediators Interleukin (IL)-4, 5 and 13 is present in the vast majority of children with asthma and most adult asthmatics. Biomarkers used in the clinic to diagnose T2 asthma are blood eosinophils⁵¹ and fraction of exhaled nitric oxide (FeNO). Sputum eosinophils are useful T2 markers, but due to the semi-invasive nature of obtaining sputum eosinophils, this test is rarely available outside specialist settings, particularly in children.

T2-low asthma is probably rare in children. It is characterized by the absence of T2 mediators and there are no established biomarkers for T2-low asthma.⁵²

The use of blood eosinophil counts as a surrogate marker of airway T2 inflammation has allowed widespread identification of T2 driven asthma and the application of biologics targeting T2 pathways. Newer biologics targeting upstream inflammatory mediators, such as thymic stromal lymphopoietin (TSLP) show clinical benefit and may provide additional options for patients who are not responding to current T2 biologics.⁵³

Fraction of Exhaled Nitric Oxide

FeNO is a marker of T2 asthma and steroid responsiveness.⁵⁴ It can be easily measured in the clinic from a breath sample.⁵⁵ Levels less than 20 parts per billion (ppb) are deemed to be normal, levels 20–35 ppb are intermediate and greater than 35 ppb are considered high in children.⁵⁵ Elevated FeNO levels in breath are present in patients with asthma and allergic rhinitis independent of asthma.⁵⁵ FeNO is often regarded as an indirect marker of eosinophilic airway inflammation,⁵⁵ however there is a poor relationship between the degree of sputum eosinophilia and FeNO⁵⁶ and this may explain why FeNO directed asthma management has not resulted in significantly improved clinical outcomes.⁵⁴ A raised FeNO is however associated with a greater risk of subsequent asthma attacks⁵⁷ and it is a marker of non-adherence to ICS.⁵⁸

Eosinophilic Asthma

Blood and sputum eosinophils above threshold levels are the clinical hallmark of T2 driven asthma, present in the majority of children and adults with asthma. Allergic asthma in adults and older children is characterised by increased numbers of circulating blood eosinophils.⁵⁹ The recognition in the 1950s that the presence of sputum eosinophils identifies patients who are responsive to corticosteroids marked the beginning of a growing interest in precision medicine in asthma. The initial non-selective study of systemic corticosteroids for asthma concluded that corticosteroids had no benefit for chronic disease management.⁶⁰ Subsequently however, Harry Morrow Brown,⁶¹ an asthma and allergy physician at Derby hospital (UK), showed that corticosteroids improved asthma control in patients with demonstrable sputum eosinophilia and he later showed similar benefits of ICS treatment in children and adults with allergic asthma.^62,63

Sputum eosinophils promote airway remodelling, subepithelial membrane thickening, goblet cell metaplasia, altered mucin composition in sputum⁶⁴ and perpetuate chronic airway inflammation⁶⁵ (see Figure 1). IL-5 is the key mediator necessary for the development, differentiation, recruitment, activation, and survival of circulating eosinophils.⁶⁶ Blood and sputum IL-5, eosinophil numbers and their secreted products correlate with the severity and frequency of asthma exacerbations.^57,67–69

Figure 1 Eosinophilic asthma inflammatory pathways. There are two aetiologies for eosinophilic inflammation in asthma: an allergic pathway triggered by allergens and a non-allergic mechanism triggered by microbes, pollutants and glycolipids. The key mediators in the pathways are depicted below. Eosinophils release cationic proteins,57 which lead to bronchial epithelial tissue damage, thus causing airways hyper-responsiveness. Eosinophils also lead to airway smooth muscle cell proliferation through increased eosinophils adhesion caused by the release of cationic proteins and the eosinophilic effect on transforming growth factor-β1 and gene coding of wingless/integrase-1 signaling. IL-13 triggers mucus hyper-secretion. Figure created with BioRender.com. Abbreviations: IgE, immunoglobulins E; IL, interleukins; ILC2, type 2 innate lymphoid cells; TCR, T-cell receptors; NK, natural killer T cell; TSLPR, thymic stromal lymphopoietin receptor; PG, prostaglandin; ECP, eosinophil cationic protein; EPX, eosinophil protein X; EPO, eosinophil peroxidase; MBP, major basic protein.

Blood Eosinophils

Peripheral blood eosinophil numbers correlate with symptom severity,⁷⁰ degree of airflow limitation⁷¹ and airways responsiveness to direct⁷² and indirect bronchial challenge⁷³ testing.

Sputum Eosinophils

The presence of airway eosinophils predicts a response to corticosteroid therapy in adult patients with asthma.⁷⁴ Elevated sputum eosinophils are also an important feature of uncontrolled asthma^75,76 and correspond to an increased risk of asthma attacks.⁷⁷ Treatment strategies in adults with asthma, based on regular monitoring and titrating of corticosteroid medication based on sputum eosinophils reduce exacerbations and lower sputum eosinophils.^75,76

The effectiveness of a management strategy based on sputum eosinophils in children has not been confirmed. One small study in older children with severe asthma found little benefit in titrating corticosteroids based on sputum eosinophil counts.⁷⁸ A number of limitations including lack of run-in period limit conclusions that can be drawn from this study.

Current Therapies for T2-High Asthma

Life-Markers

There is a need for shared decision-making between healthcare professionals, and children and their parents. Before even considering a biological therapy, healthcare professionals must assess whether the children and their carers are able to cope with injections and the burden of this treatment.⁷⁹

IgE Blockers

Immunoglobulin E (IgE) is a class of antibody discovered in 1966, which is increased in patients with atopic illnesses such as asthma.⁸⁰ IgE production is mediated by T-helper 2 cells through the release of IL-4 and IL-13 cytokines.⁸¹ In asthma, IgE exerts its immunological effects by binding to the high-affinity receptor for IgE (FcεRI) expressed on mast cells, basophils, dendritic cells, airway smooth muscle cells, and eosinophils.⁸² This leads to the release of pro-inflammatory mediators including histamine, tryptase, heparin, and chymase, which in turn trigger the early and late phase asthma reactions.⁸³

Omalizumab

Omalizumab is a humanized monoclonal antibody, which binds to free systemic IgE. It was approved in 2003 by the US Food and Drug Administration as the first biologic for the treatment of asthma. The resulting Omalizumab–IgE complex does not bind to FcεRI,⁸⁴ thus reducing the downstream inflammatory cascade seen in allergic asthma.

Numerous RCTs have demonstrated the beneficial effects of omalizumab as an adjunct to asthma management, summarised in a 2014 Cochrane review.⁸⁵ The authors calculated that in eligible patients receiving omalizumab, asthma attacks are reduced (OR 0.55 CI 0.42–0.60), hospital admissions decreased (OR 0.16 CI 0.06–0.42), and SABA usage is reduced (mean difference −0.39 puffs per day, CI 0.55–0.2).⁸⁵ Only 3 of the 25 trials included in this review were paediatric studies.^86–88

A recent meta-analysis of 86 observational studies confirms real-world efficacy of omalizumab at reducing asthma attacks, and improving patient-reported outcomes and lung function in patients with severe allergic asthma.⁸⁹ Discontinuation of omalizumab is associated with a decline in asthma control.⁹⁰

Omalizumab reduced the dose of ICS needed to control symptoms and the frequency of asthma attacks during the steroid-reduction phase (18.2 vs 38.5% for placebo) in a double-blind, placebo-controlled RCT in children aged 6–12 years with moderate to severe allergic asthma. Children also reported better quality of life.⁸⁷ Another RCT in children aged 6 to 11 years with uncontrolled moderate-to-severe persistent allergic asthma similarly showed a reduction in asthma attacks by 43%.⁸⁶ The substantial reduction in asthma attacks in children on omalizumab has also been confirmed in other real-world settings.⁹¹

The multicentre ICATA study⁸⁸ demonstrated the seasonal beneficial effects of omalizumab in children and young people aged six to 20 years with persistent allergic asthma. Children were randomised to subcutaneous placebo or omalizumab and the study showed a doubling of asthma attacks in the placebo group in the autumn and spring which was not seen in the omalizumab arm.⁸⁸ Adherence issues in the placebo group may have influenced the findings from this trial.

Omalizumab is generally well tolerated. Upper respiratory tract infection, headache and urticaria are the most frequently reported side effects.⁹²

Anti-IL-5 Therapy

Mepolizumab

Mepolizumab was the first licensed monoclonal antibody developed targeting the IL-5 signalling pathway. It is a humanised monoclonal antibody, belonging to the IgG subclass, which blocks the binding of IL-5 to its receptor on eosinophils.

The initial findings from two early trials of mepolizumab were disappointing. Patients with mild asthma were randomised to intravenous mepolizumab or placebo. Although both blood and sputum eosinophil counts fell significantly in the treatment groups, no significant improvement in FEV_1, or airway hyper-responsiveness were observed between the groups.⁹³ A second RCT in adults with moderate-to-severe asthma on daily ICS similarly showed a fall in blood and sputum eosinophils in the treatment groups, but no significant changes in lung function or symptoms.⁹⁴

However, both these early trials included an unselected cohort of asthma patients, without stratifying for phenotype. The growing interest in precision medicine prompted further investigations into the potential use of anti-IL5 therapy in patients with a known treatable trait, ie, evidence of eosinophilic asthma.⁹⁵ Two subsequent small studies, which included only patients with a history of recurrent asthma attacks and raised sputum eosinophils, found a substantial reduction by 43% in asthma attacks over 12 months in the mepolizumab arm⁹⁶ and a reduction in daily OCS.⁹⁷

These results have since been replicated in several large Phase 3 trials.^98–101 In adults with severe eosinophilic asthma, there was a reduction in asthma attacks,^98,102 an improvement in quality of life,¹⁰¹ and a reduction in the need for OCS.¹⁰⁰ The efficacy of mepolizumab is sustained over the whole 4-week dosing period⁹⁵ and is proportional to the baseline blood eosinophil count.⁹⁸ Patient reported quality of life indices were no different between the mepolizumab and placebo groups and there was a limited impact on lung function.⁹⁸

In children, although patients ≥12 years were eligible to participate in the phase 3 mepolizumab trials, fewer than 40 adolescents were recruited across all studies.¹⁰³ In the 6-to-11 year age group, there is only one small trial including 30 children, which report mainly on safety and pharmacokinetic data.¹⁰⁴ The limited efficacy data reported in this small study demonstrated similar findings to those from the adult studies in terms of reduction in frequency of asthma attacks.

The license for mepolizumab was initially for adults and then extended to children ≥6 years in 2018 by the EMA, and 2019 by the FDA (US Food and Drug Administration).

GINA recommends the consideration of anti-IL5 therapy for adults and children with above threshold blood eosinophils, severe asthma and frequent asthma attacks.¹⁴

Reslizumab

Reslizumab is an IgG4/k monoclonal antibody that binds to IL-5 with high specificity. It is used for the treatment of severe uncontrolled eosinophilic asthma, improves asthma control, quality of life and FEV_1.¹⁰⁵ It is licensed in patients >18 years with baseline blood eosinophils ≥400 cells/μL.¹⁰⁶ Studies of reslizumab in children have ended early because no benefits were found in the 12 to 17 year age group.¹⁰⁷

There are still concerns about the route of administration and the use of this drug in the wider context.³⁴

Benralizumab

Benralizumab is an anti-eosinophil monoclonal antibody which is an IgG1/k antagonist of the α-chain of the human IL-5 receptor. Benralizumab is the only drug that induces eosinophil apoptosis through cellular toxicity mechanisms (antibody-dependent cell-mediated cytotoxicity) thereby reducing eosinophils in tissues.¹⁰⁸ Its clinical effect is independent of circulating levels of IL-5, raised during an asthma attack.¹⁰⁹ Benralizumab reduces asthma attacks and leads to improvement in FEV_1.¹¹⁰ Benralizumab is an effective steroid-sparing agent in adults.¹¹¹ Benralizumab is licensed for use in children aged 12 years and older in the USA, but only for adults in Europe, pending clinical trials in children.¹¹²

Anti-IL-4/IL-13 Therapy

Dupilumab

IL-4 and IL-13 are two closely related drivers of T2 inflammation, activating the same alpha subunit of the IL-4 receptor (IL-4Rα).¹¹³ Both cytokines are secreted by TH2 and type-2 innate lymphoid cells (ILC-2). IL-4, and to a lesser extent IL-13, upregulate IgE synthesis by inducing B-cell class switching; whilst IL-13 plays a key role in airway hyper-responsiveness, increasing mucus production, and airway remodelling.

Dupilumab is a fully humanized monoclonal antibody, which selectively binds to IL-4Rα, thus acting as a dual antagonist for both IL-4 and IL-13.¹¹⁴

In an early phase IIa trial, 104 adults (≥18 years) with moderate-severe asthma and elevated eosinophils in blood or sputum were randomised to receive dupilumab or placebo for up to 12 weeks. Fewer asthma attacks occurred in the treatment arm (odds ratio 0.08) together with lung function improvements and better asthma control.¹¹³ These results were replicated in three subsequent larger RCTs; a phase IIb trial which included 776 adults, and two phase 3 trials which also included adolescents (≥12 years of age).^115,116 Fewer asthma attacks (~50%),¹¹⁵ and reduced oral corticosteroid dependence were observed in patients receiving dupilumab when compared with placebo.¹¹⁷

Dupilumab appears to be effective in patients with or without evidence of allergic asthma (raised IgE or specific IgE to aeroallergens),¹¹⁸ and regardless of baseline ICS dose or lung function. However, greater benefit is observed in patients with higher baseline eosinophil and FeNO levels.^115,118

Of 1902 patients enrolled into the phase 3 dupilumab trial,¹¹⁵ 107 were adolescents aged 12–17 years. In a post hoc analysis of this adolescent sub-group, significant improvements in lung function and frequency of attacks, at a similar rate seen in adults, were observed using the 200 mg dosing regimen.¹¹⁹ Dupilumab is licensed for children with asthma aged ≥12 years by the FDA.

In the 6–11 year age group, a randomised controlled trial of dupilumab versus placebo in children with uncontrolled persistent asthma has recently been completed (NCT02948959).¹²⁰ Although no published data is currently available, an early company press release suggests that the efficacy of dupilumab in children aged 6–11 with asthma is favourable.

For dosing and licensing of the five licensed biologics, please refer to Table 1. See Figure 2 for the mechanism of action of the biologics.

Table 1 Licensed Biologics Used for Severe Asthma

Figure 2 Licensed mediator cascade of biologics used in eosinophilic asthma. The figure below shows the targets for the licensed biologics. Omalizumab is an IgE-blocker. Mepolizumab, reslizumab and benralizumab are anti IL-5 agents. Dupilumab is an Anti-IL-4/anti-IL-13 agent. Figure created with BioRender.com. Abbreviations: IgE, Immunoglobulins E; IL, interleukins; ILC2, type 2 innate lymphoid cells; TCR, T-cell receptors; NK, natural killer T cell; TSLPR, thymic stromal lymphopoietin receptor; PG, prostaglandin.

Targeting Upstream Mediators

Currently licenced biologic treatments for severe asthma target downstream mediators. Monoclonal antibodies against upstream mediators that may have an effect in T2-low asthma are in development. Of particular interest are biologics against the alarmins TSLP, IL-25 and IL-33. Alarmins are mediators originating from airway epithelial cells in response to triggers such as allergens, pathogens including viruses and environmental triggers. There are no clinical trials targeting IL-25 or 33, but the monoclonal antibody tezepelumab that blocks TSLP has shown promise and is currently evaluated in phase 3 trials that have been completed.

Thymic Stromal Lymphopoietin (TSLP)

Tezepelumab is a human monoclonal antibody that binds to TSLP, blocking it from interacting with its high-affinity receptor complex composed of TSLP-receptor and IL-7Rα.^121,132,133 TSLP is an airway epithelial cytokine released in response to environmental triggers such as viruses and aeroallergens.^122,123 Several cells involved in asthma pathophysiology express the TSLP receptor including eosinophils, mast cells, innate type-2 lymphoid cells, lymphocytes, dendritic cells and airway smooth muscle cells.¹²⁴ In children, TSLP has been implicated in the pathobiology of allergic rhinitis.¹²⁵

TSLP strongly stimulates a T2 cytokine response but due to its upstream position evidence emerges that it may be useful in T2-low asthma. Interestingly, the results were similar among T2 high and T2-low asthmatics in a Phase 2 study in adults with severe asthma.¹²⁶ Based on the positive results of the phase 2 study, tezepelumab is now the subject of two phase 3 studies. The NAVIGATOR study is assessing the effect of tezepelumab on the annual rate of asthma exacerbation in patients aged 12–80 years⁵³ while the SOURCE study is an OCS dose reduction study in patients aged 18–80 years. The data is not published but initial press releases suggest that tezepelumab reduces the annual rate of asthma exacerbations in adults with severe asthma,¹²⁷ but is ineffective at reducing OCS requirement without loss of asthma control.¹²⁸ No data relating to adolescents is currently available.

Treatment for T2-Low Severe Asthma

There are currently no effective targeted treatments for patients with severe, T2-low asthma. Targeting upstream mediators such as TSLP offers some hope for this group.⁵³

Macrolide Antibiotics

The macrolide antibiotics azithromycin and clarithromycin have been used to treat neutrophilic asthma.³⁴ A trial of azithromycin in pauci-inflammatory asthma in adults also showed a significant reduction in number of attacks.¹²⁹ Oral azithromycin add-on therapy reduced asthma attacks in adults with persistent uncontrolled eosinophilic and non-eosinophilic asthma in the AMAZES trial¹³⁰ and is recommended as a treatment by the ERS/ATS guidelines on severe asthma in adults.¹⁵ The guidelines advise against the use of chronic macrolides in children with severe asthma.¹³¹

Other Precision Treatments for Severe Asthma

Fevipiprant

This prostaglandin D₂ receptor 2 antagonist showed promise in phase 2 clinical trials,¹³² but the recent phase 3 trials LUSTER-1 and LUSTER-2 showed no statistically significant reduction in asthma exacerbations in adults.¹³³

Bronchial Thermoplasty

This treatment delivers targeted heat to the airway wall to reduce airway smooth muscle mass. It also modulates mucosal inflammatory responses and collagen deposition.¹³⁴ There are several trials of BT in asthma including Asthma Intervention Research (AIR)-1¹³⁵ and AIR-2¹³⁶ showing that BT can lead to a reduction in asthma attacks, an improvement in lung function and an improvement in the quality of life. The benefits appear to be sustained over 10 years following the procedure.¹³⁷ This treatment is not approved for children.

Future Directions

Notwithstanding some geographical variation, approximately one child in every 100 to 150 children has severe asthma that is uncontrolled on high dose ICS or regular OCS. These children require careful assessment and phenotyping and many would benefit from treatment with biologics. A few monoclonal antibodies are already currently licensed for the treatment of severe asthma in children and this number is likely to increase. Biologics are frequently only evaluated in small numbers of children as part of adult focussed asthma studies, a situation that is inadequate. Future development of targeted biologic treatments should include separate high-quality studies in children to test efficacy and safety.

Conclusion

Severe asthma in children places a substantial burden on children, their carers and healthcare services. It is a heterogeneous condition and as our knowledge of phenotypes, endotypes and the genetics of asthma improves, we will increasingly be able to deliver personalised precision care to children, rather than using a “one size fits all” approach. Precision medicine in asthma allows the clinical teams to tailor treatment plans and use the most appropriate biological treatment where standard care is not adequately controlling the asthma. The increasing availability of biologics for children with severe asthma presents an opportunity to improve the lives of children with severe asthma. Ongoing challenges include the need for better phenotyping of severe childhood asthma with ideally minimally invasive or non-invasive tests and the recruitment of more children to phase 3 studies of novel targeted biological treatments.